The Future of Neurokinin-Targeted Therapies in Patients With VMS
A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on patient quality of life, noting ongoing needs for long-term safety data and improved accessibility.
Video content above is prompted by the following:
- How might these therapies fit into combination treatment strategies, and what combinations seem most promising?
- How do you see the broader implications of neurokinin-targeted therapies on patient outcomes and quality of life? What are the unmet needs with these therapies?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
